{"id":4645,"date":"2025-04-24T11:35:53","date_gmt":"2025-04-24T02:35:53","guid":{"rendered":"https:\/\/www.nanomrna.co.jp\/en\/?page_id=4645"},"modified":"2025-04-24T11:35:53","modified_gmt":"2025-04-24T02:35:53","slug":"mrna_ip","status":"publish","type":"page","link":"https:\/\/www.nanomrna.co.jp\/en\/business\/mrna_ip\/","title":{"rendered":"mRNA drug Discovery"},"content":{"rendered":"<div class=\"boxInner\">\n<h2 class=\"pgtit_2\">Our Business<\/h2>\n<div class=\"boxsubInner mb40\">\n<p class=\"pgtit_8 f_w600 text_c mb20\"><span class=\"font_1\">Global leader<\/span> <span class=\"font_2\">for<\/span> <span class=\"font_3\">\u201cmRNA for<\/span> <span class=\"font_6\">health\u201d<\/span><\/p>\n<div class=\"bg_clo_1\">\n<p class=\"cl_3 f_w600 font_sz20 indent\">\u30fbGenerate intellectual property (IP) on mRNA therapeutics in-house and in collaboration with companies and academia, and license out drug candidates<\/p>\n<p class=\"cl_3 f_w600 font_sz20 indent\">\u30fbContract research and development of mRNA vaccines and mRNA therapeutics for domestic and foreign companies<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<div class=\"boxsubInner mb40\">\n<p class=\"pgtit_2\">mRNA drug discovery platform of NANO MRNA<\/p>\n<div class=\"specialpoint mb10\">\n<h4>Pioneer in mRNA drug discovery<\/h4>\n<ul class=\"list03\">\n<li>The only company in Japan with proven expertise<\/li>\n<li>Multiple promising development candidates<\/li>\n<li>Value chain encompasses the process from seed to development candidate<br \/><span class=\"font_sz14\">Capital and business alliance with AXCELEAD<sup>*<\/sup><\/span><\/li>\n<li>Comprehensive range of DDS <span class=\"font_sz14\">(Drug Delivery System)<\/span> selection solutions based on our experience<\/li>\n<\/ul><\/div>\n<p class=\"indent font_sz14\">*AXELEAD: HD company that owns AXELEAD Drug Discovery Partners (ADDP) and ARCALIS, among others.<\/p>\n<\/p><\/div>\n<\/p><\/div>\n<div id=\"modelip\" class=\"pagenailink\"><\/div>\n<div class=\"boxInner\">\n<h2 class=\"pgtit_2\">Business Model<\/h2>\n<div class=\"boxsubInner mb40\">\n<p class=\"pgtit_2\">Value chain and license-out models for mRNA drug discovery<\/p>\n<figure><img decoding=\"async\" class=\"imgblock\" src=\"https:\/\/www.nanomrna.co.jp\/en\/nanocms\/wp-content\/themes\/original\/img\/business\/img_01_25.svg\"><\/figure>\n<\/p><\/div>\n<div class=\"boxsubInner\">\n<p class=\"pgtit_2\">Revenue model<\/p>\n<figure><img decoding=\"async\" class=\"imgblock\" src=\"https:\/\/www.nanomrna.co.jp\/en\/nanocms\/wp-content\/themes\/original\/img\/business\/img_02_25.svg\"><\/figure>\n<\/p><\/div>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Our Business Global leader for \u201cmRNA for health\u201d \u30fbGenerate intellectual property (IP) on mRNA therapeutics in- [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":3912,"menu_order":10,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/4645"}],"collection":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/comments?post=4645"}],"version-history":[{"count":1,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/4645\/revisions"}],"predecessor-version":[{"id":4646,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/4645\/revisions\/4646"}],"up":[{"embeddable":true,"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/pages\/3912"}],"wp:attachment":[{"href":"https:\/\/www.nanomrna.co.jp\/en\/wp-json\/wp\/v2\/media?parent=4645"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}